Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

You may also be interested in...

Celgene Flexes Its Muscles

In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?

One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says

Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.

Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny

Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts